Sensitivity and resistance to DNA damage response inhibitors in acute myeloid leukemia with spliceosome mutations
Bidragets beskrivning
Acute myeloid leukemia (AML) is an aggressive blood cancer treated with combination chemotherapy. The development of therapy for AML has been slow, and the standard chemotherapy has remained unchanged for decades. Spliceosome mutations are recurrent drivers of AML pathogenesis. Recent research shows that spliceosome mutations induce a DNA damage response vulnerability that can be targeted therapeutically. This study identifies new drug sensitivities in spliceosome mutated AML.
Visa merStartår
2020
Slutår
2024
Beviljade finansiering
Finansiär
Finlands Akademi
Typ av finansiering
Forskardoktorer
Utlysning
Övriga uppgifter
Finansieringsbeslutets nummer
334273
Vetenskapsområden
Biomedicinska vetenskaper
Forskningsområden
Biolääketieteet
Identifierade teman
cancer